An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing ...

Managing high blood pressure is essential for reducing the risk of heart disease and stroke, which are among the leading ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Epigenetic drugs induce heritable modifications to genetic material that result in changes in gene expression without ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

0:09 | NKT-2152 is a HIF-2α inhibitor, so it will bind to HIF-2α to prevent heterodimerization with HIF-1 beta. And this is ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Ardelyx's tenapanor targets IBS-C and hyperphosphatemia in CKD patients, showing strong revenue growth. Read why I downgrade ...